These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 1876785)

  • 21. Discussion of individual bioequivalence by M.-L. Chen.
    Gould AL
    J Biopharm Stat; 1997 Mar; 7(1):23-9. PubMed ID: 9056584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are the current bioequivalence standards sufficient for the acceptance of narrow therapeutic index drugs? Utilization of a computer simulated warfarin bioequivalence model.
    Walker SE; Friesen MH
    J Pharm Pharm Sci; 1999; 2(1):15-22. PubMed ID: 10951658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Group sequential extensions of a standard bioequivalence testing procedure.
    Gould AL
    J Pharmacokinet Biopharm; 1995 Feb; 23(1):57-86. PubMed ID: 8576845
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The bioequivalence of highly variable drugs and drug products.
    Midha KK; Rawson MJ; Hubbard JW
    Int J Clin Pharmacol Ther; 2005 Oct; 43(10):485-98. PubMed ID: 16240706
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extension to the use of tolerance intervals for the assessment of individual bioequivalence.
    Esinhart JD; Chinchilli VM
    J Biopharm Stat; 1994 Mar; 4(1):39-52. PubMed ID: 8019583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Review and use of decision rules for bioequivalence trials].
    Nicolas P; Tod M; Petitjean O
    Therapie; 1993; 48(1):15-22. PubMed ID: 8356540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sample size considerations for establishing clinical bioequivalence of allergen formulations.
    Rabin RL; Slater JE; Lachenbruch P; Pastor RW
    Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 2003; (94):24-33. PubMed ID: 15119019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of average, population and individual bioequivalence in two- and four-period crossover studies.
    Wijnand HP
    Comput Methods Programs Biomed; 2003 Jan; 70(1):21-35. PubMed ID: 12468124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A method for the evaluation of individual bioequivalence.
    Endrenyi L
    Int J Clin Pharmacol Ther; 1994 Sep; 32(9):497-508. PubMed ID: 7820334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PhRMA perspective on population and individual bioequivalence.
    Barrett JS; Batra V; Chow A; Cook J; Gould AL; Heller AH; Lo MW; Patterson SD; Smith BP; Stritar JA; Vega JM; Zariffa N
    J Clin Pharmacol; 2000 Jun; 40(6):561-70. PubMed ID: 10868305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The U.S. draft guidance regarding population and individual bioequivalence approaches: comments by a research-based pharmaceutical company.
    Hauschke D; Steinijans VW
    Stat Med; 2000 Oct; 19(20):2769-74. PubMed ID: 11033574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Equivalence assessment for interchangeability based on two-sided tests.
    Dong X; Tsong Y
    J Biopharm Stat; 2014; 24(6):1312-31. PubMed ID: 25032976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative assessment of the switchability of generic products.
    Karalis V; Bialer M; Macheras P
    Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An approximate approach to sample size determination in bioequivalence testing with multiple pharmacokinetic responses.
    Tsai CA; Huang CY; Liu JP
    Stat Med; 2014 Aug; 33(19):3300-17. PubMed ID: 24771655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of outlying data in bioavailability/bioequivalence studies.
    Liu JP; Weng CS
    Stat Med; 1991 Sep; 10(9):1375-89. PubMed ID: 1925168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Veterinary drug bioequivalence determination.
    Toutain PL; Koritz GD
    J Vet Pharmacol Ther; 1997 Apr; 20(2):79-90. PubMed ID: 9131533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An approach for sample size determination of average bioequivalence based on interval estimation.
    Chiang C; Hsiao CF
    Stat Med; 2017 Mar; 36(7):1068-1082. PubMed ID: 28070984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel approach to the specification of in-vitro dissolution boundaries based on regulatory requirements for bioequivalence.
    Steinijans VW; Dietrich R; Trautmann H; Sauter R; Benedikt G
    Arzneimittelforschung; 1988 Aug; 38(8A):1238-40. PubMed ID: 3190812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kullback-Leibler divergence for evaluating bioequivalence.
    Dragalin V; Fedorov V; Patterson S; Jones B
    Stat Med; 2003 Mar; 22(6):913-30. PubMed ID: 12627409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The bootstrap in bioequivalence studies.
    Pigeot I; Hauschke D; Shao J
    J Biopharm Stat; 2011 Nov; 21(6):1126-39. PubMed ID: 22023681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.